PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evalute the efficacy and safety of PD-1 antibody combined
with Dasatinib as third-line therapy for NSCLC patients with ARID1A mutation until disease
progression or intolerable toxicity or patients withdrawal of consent. The target sample size
is 30+individuals. The primary endpoint of this study is PFS、ORR、OS and the secondary
endpoint is toxicity.